Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Discovery of Two GSK3β Inhibitors from Sophora flavescens Ait. using Structure-based Virtual Screening and Bioactivity Evaluation
Dabo Pan; Yong Zeng; Dewen Jiang; Yonghao Zhang; Mingkai Wu; Yaxuan Huang; Minzhen Han; Xiaojie JinShow moreShow less
1. Department of Medical Technology, Qiandongnan Vocational and Technical College for Nationalities, Kaili, 556000, China;; 2. Department of Pharmacy, The Second Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Kaili, 556000, China;; 3. College of Pharmacy, The Affiliated Dazu’s Hospital of Chongqing Medical University, Dazu, 402360, China;; 4. College of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, 730000, ChinaShow moreShow less
Exploring the Potential Mechanisms of Danshen for the Treatment of Ulcerative Colitis based on Serum Pharmacochemistry, Gene Expression Profiling, and Network Pharmacology: Regulation of Cell Apoptosis and Inflammatory Response
Run-Xiang Zhai; Meng-Yu Wang; Hai-Tao Du; Chun-Xiao Yan; Zi-Wei Li; Kuo Xu; Hui Li; Xian-Jun Fu; Xia RenShow moreShow less
1. Marine Traditional Chinese Medicine Research Center, Qingdao Academy of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Qingdao, 266114, China;; 2. Qingdao Key Technology Innovation Center of Marine Traditional Chinese Medicine Deep Development and Industrialization, Qingdao, 266114, China;; 3. State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China;; 4. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, ChinaShow moreShow less
Decoding the Knacks of Ellagitannin Lead Compounds to Treat Nonalcoholic Fatty Liver Disease using Computer-aided Drug Designing
Hina Shahid; Muhammad Ibrahim; Wadi B. Alonazi; Zhanyou ChiShow moreShow less
1. MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, China;; 2. State Key Laboratory of Rice Biology and Breeding, Key Laboratory of Molecular Biology of Crop Pathogens and Insects, Institute of Biotechnology, Zhejiang University, Hangzhou, 310058, China;; 3. Health Administration Department, College of Business Administration, King Saud University, Riyadh, Saudi ArabiaShow moreShow less
Exploration of Pharmacological Mechanisms of Dapagliflozin against Type 2 Diabetes Mellitus through PI3K-Akt Signaling Pathway based on Network Pharmacology Analysis and Deep Learning Technology
Jie Wu; Yufan Chen; Shuai Shi; Junru Liu; Fen Zhang; Xingxing Li; Xizhi Liu; Guoliang Hu; Yang DongShow moreShow less
1. Department of Cardiology, Jinhua People's Hospital, Jinhua, Zhejiang, China;; 2. Department of Blood Donation Service, Central Blood Station of Jinhua, Jinhua, Zhejiang, China;; 3. Department of IVF, Jinhua People's Hospital, Jinhua, Zhejiang, China;; 4. Department of Endocrinology, Jinhua People's Hospital, Jinhua, Zhejiang, China;; 5. Department of Ultrasound in Medicine, Jinhua People's Hospital, Jinhua, Zhejiang, ChinaShow moreShow less
Integrated Bioinformatics Analysis and Target Drug Prediction of Inflammatory Bowel Disease Co-existent Diabetes Mellitus
Lili Yang; Ning Wang; Yutong Wang; Wen Li; Ziyang Kong; Bin Zhang; Yaoyao BianShow moreShow less
1. Jingwen Library, Nanjing University of Chinese Medicine, Nanjing, 210023, China;; 2. Jiangsu Provincial Engineering Center of TCM External Medication Researching and Industrializing, Nanjing University of Chinese Medicine, Nanjing, 210023, China;; 3. School of Acupuncture-Moxibustion and Tuina, School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, 210023, China;; 4. Department of Gastroenterology, Ningbo Municipal Hospital of TCM, Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, 315012, ChinaShow moreShow less
FAQ
How long does Current Computer-Aided Drug Design take to review a manuscript?
As of 2026-11-19, CrushSCI has 5 complete review records for Current Computer-Aided Drug Design. The fastest paper went from submission to acceptance in 74 days (Decoding the Knacks of Ellagitannin Lead Compounds to Treat Nonalcoholic Fatty Liver Disease using Computer-aided Drug Designing, received 2024-06-09, accepted 2024-08-22); the slowest took 152 days. The average is 92.6 days and the median is 79 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
